Proactive Investors - Run By Investors For Investors

Pressure BioSciences Inc looks ahead to technology showcase at Boston proteome conference

The group’s ‘cell opening’ technology will be showcased as part of a workshop at the US Human Proteome Organization (US HUPO) annual conference in Boston next month.
Pressure BioSciences Inc looks ahead to technology showcase at Boston proteome conference
Next-generation solutions can industrialise enable life science research, PBIO says.

Pressure Bioscience (OTCMKTS:PBIO) told investors that its ‘cell opening’ technology will be showcased at an upcoming conference focussing on  proteomes.

The company’s partner SCIEX, a life science analytics specialist, is presenting and leading a workshop at the annual US Human Proteome Organization (US HUPO) conference in Boston between March 13 and 16.

Representatives of SCIEX, Pressure Bioscience and gene and protein analysis specialist Advaita Bioinformatics will share examples of how next-generation solutions can enable life science researchers to unlock the potential of their discoveries, the company said in a statement.

It highlighted that examples presented via the workshop will show how SCIEX's next-generation mass spectrometry-based solutions - combined with PBI's PCT platform and Advaita's iPathwayGuide - can industrialize research workflows.

Pressure Bioscience senior scientist Vera Gross will, as part of the showcase, give a presentation discussing the on advances of quantitative SWATH-MS technology with the introduction of new PCT-based sample preparation techniques.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use